[go: up one dir, main page]

PE20120602A1 - ATROPISOMEROS DE 2-[(6-AMINO-9H-PURIN-9-IL)METIL]-5-METIL-3-o-TOLILQUINAZOLIN-4(3H)-ONA - Google Patents

ATROPISOMEROS DE 2-[(6-AMINO-9H-PURIN-9-IL)METIL]-5-METIL-3-o-TOLILQUINAZOLIN-4(3H)-ONA

Info

Publication number
PE20120602A1
PE20120602A1 PE2011001710A PE2011001710A PE20120602A1 PE 20120602 A1 PE20120602 A1 PE 20120602A1 PE 2011001710 A PE2011001710 A PE 2011001710A PE 2011001710 A PE2011001710 A PE 2011001710A PE 20120602 A1 PE20120602 A1 PE 20120602A1
Authority
PE
Peru
Prior art keywords
methyl
purin
amino
atropisomer
tolilquinazolin
Prior art date
Application number
PE2011001710A
Other languages
English (en)
Inventor
Jerry B Evarts
Roger G Ulrich
Original Assignee
Gilead Calistoga Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42289320&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120602(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Calistoga Llc filed Critical Gilead Calistoga Llc
Publication of PE20120602A1 publication Critical patent/PE20120602A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UN ATROPISOMERO OPTICAMENTE ACTIVO DEL COMPUESTO 2-((6-AMINO-9H-PURIN-9-IL)METIL)-5-METIL-3-O-TOLILQUINAZOLIN-4(3H)-ONA QUE SE OBTIENE POR SEPARACION DE UNA MEZCLA RACEMICA, EL CUAL COMPRENDE EL ATROPISOMERO 1(R) Y EL ATROPISOMERO 1(S). TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHO COMPUESTO INHIBE LAS ISOFORMAS DE LA FOSFATIDILINOSITOL-3,4,5-TRIFOSFATO QUINASA ? (PI3K?) SIENDO UTIL EN EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS Y CANCER
PE2011001710A 2009-03-24 2010-03-24 ATROPISOMEROS DE 2-[(6-AMINO-9H-PURIN-9-IL)METIL]-5-METIL-3-o-TOLILQUINAZOLIN-4(3H)-ONA PE20120602A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16298009P 2009-03-24 2009-03-24
US23155009P 2009-08-05 2009-08-05

Publications (1)

Publication Number Publication Date
PE20120602A1 true PE20120602A1 (es) 2012-05-21

Family

ID=42289320

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001710A PE20120602A1 (es) 2009-03-24 2010-03-24 ATROPISOMEROS DE 2-[(6-AMINO-9H-PURIN-9-IL)METIL]-5-METIL-3-o-TOLILQUINAZOLIN-4(3H)-ONA

Country Status (19)

Country Link
US (1) US8440677B2 (es)
EP (1) EP2411391A1 (es)
JP (1) JP2012521994A (es)
KR (1) KR20120002995A (es)
CN (1) CN102439012A (es)
AP (1) AP2011005943A0 (es)
AU (1) AU2010229968A1 (es)
BR (1) BRPI1012333A2 (es)
CA (1) CA2756347A1 (es)
CL (1) CL2011002359A1 (es)
CO (1) CO6450655A2 (es)
EA (1) EA019499B1 (es)
EC (1) ECSP11011412A (es)
IL (1) IL215251A0 (es)
MX (1) MX2011009955A (es)
NZ (1) NZ595307A (es)
PE (1) PE20120602A1 (es)
SG (1) SG174529A1 (es)
WO (1) WO2010111432A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
WO2005016348A1 (en) * 2003-08-14 2005-02-24 Icos Corporation Method of inhibiting immune responses stimulated by an endogenous factor
RS55551B1 (sr) 2004-05-13 2017-05-31 Icos Corp Hinazolinoni kao inhibitori humane fosfatidilinozitol 3-kinaze delta
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
KR101664511B1 (ko) 2008-11-13 2016-10-11 길리아드 칼리스토가 엘엘씨 혈액 종양에 대한 요법
BRPI1012333A2 (pt) 2009-03-24 2016-03-29 Gilead Calistoga Llc atropisômeros de derivados de 2-purinil-3-tolil-quinazolinonas e métodos de uso
JP2012524126A (ja) * 2009-04-20 2012-10-11 ギリアド カリストガ リミテッド ライアビリティ カンパニー 固形腫瘍の治療方法
WO2010138577A1 (en) * 2009-05-29 2010-12-02 Merck Sharp & Dohme Corp. Radiolabeled pde10 inhibitors
CN102647987A (zh) * 2009-07-21 2012-08-22 吉里德卡利斯托加公司 使用pi3k抑制剂治疗肝脏障碍
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
EP2518071A1 (en) * 2011-04-29 2012-10-31 Almirall, S.A. Imidazopyridine derivatives as PI3K inhibitors
EP2518070A1 (en) * 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
US9949979B2 (en) 2011-12-15 2018-04-24 Novartis Ag Use of inhibitors of the activity or function of PI3K
PT2834241T (pt) 2012-03-05 2021-02-05 Gilead Calistoga Llc Formas polimórficas de (s)-2-(1-(9h-purin-6-ilamino)propil)-5-fluoro-3-fenil quinazolina-4(3h)-ona
TWI617561B (zh) 2012-03-13 2018-03-11 瑞斯比維特有限公司 呈晶體型式之新穎化合物，包含其之醫藥組成物，製備該化合物之方法及包括該組成物之吸入裝置
AU2013285081B2 (en) 2012-07-04 2017-01-12 Rhizen Pharmaceuticals Sa Selective PI3K delta inhibitors
WO2014015523A1 (en) * 2012-07-27 2014-01-30 Hutchison Medipharma Limited Novel heteroaryl and heterocycle compounds, compositions and methods
WO2014060431A1 (en) * 2012-10-16 2014-04-24 Almirall, S.A. Pyrrolotriazinone derivatives as pi3k inhibitors
HK1211027A1 (en) * 2012-10-16 2016-05-13 Almirall, S.A. Pyrrolotriazinone derivatives as pi3k inhibitors
CN111904962A (zh) 2012-11-08 2020-11-10 理森制药股份公司 含有PDE4抑制剂和PI3 δ或双重PI3 δ-γ激酶抑制剂的药物组合物
TW201522341A (zh) 2013-03-15 2015-06-16 Respivert Ltd 化合物
AR095353A1 (es) 2013-03-15 2015-10-07 Respivert Ltd Compuesto
UY35675A (es) 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona
CN104418849B (zh) * 2013-09-02 2020-04-21 广东东阳光药业有限公司 取代的氨基嘧啶类化合物及其使用方法和用途
RU2683793C2 (ru) 2013-09-22 2019-04-02 Калитор Сайенсез, ЛЛС Замещенные аминопиримидиновые соединения и способы их использования
US9567337B2 (en) 2013-12-20 2017-02-14 Gilead Calistoga Llc Process methods for phosphatidylinositol 3-kinase inhibitors
US9708327B2 (en) 2013-12-20 2017-07-18 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
BR112016027674A2 (pt) 2014-05-27 2017-08-15 Rhizen Pharmaceuticals Sa Formas melhoradas de um inibidor seletivo de pi3k delta para uso em formulações farmacêuticas
BR112016024538A2 (pt) * 2014-05-27 2017-08-15 Almirall Sa sais de adição de (s)-2-(1-(6-amino-5-cianopirimidin-4-ilamino)etil)-4-oxo-3-fenil-3,4-di-hidro¬pirrolo[1,2-f][1,2,4]triazina-5-carbonitrila
HK1231476A1 (zh) 2014-06-13 2017-12-22 吉利德科学公司 磷脂酰肌醇3-激酶抑制剂
CU24428B1 (es) 2014-07-04 2019-06-04 Lupin Ltd Derivados de quinolizinona como inhibidores de pi3k
EP3334430B1 (en) * 2015-08-13 2025-02-26 San Diego State University Research Foundation Atropisomerism for increased kinase inhibitor selectivity
ES2959563T3 (es) 2016-01-11 2024-02-27 Univ London Queen Mary Inhibidores de pi3k p-delta 110 para su uso en la administración de virus en el tratamiento del cáncer
EP3475276B1 (en) 2016-06-22 2021-03-31 The United States of America, as represented by the Secretary, Department of Health and Human Services Thiazole derivatives useful as mutant idh1 inhibitors for treating cancer
US10016425B2 (en) 2016-11-03 2018-07-10 King Saud University Anti-ulcerative colitis compound
EP3828184A4 (en) * 2018-08-21 2022-05-04 Medshine Discovery Inc. PYRAZOLOPYRIMIDI DERIVATIVES AND USE THEREOF AS A PI3K INHIBITOR
EP4132910A1 (en) 2020-04-10 2023-02-15 GB002, Inc. Kinase inhibitors

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1053063A (es) 1963-05-18
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
DE2027645A1 (de) 1970-06-05 1971-12-09 Byk Gulden Lomberg Chemische Fa bnk GmbH, 7750 Konstanz Piperazinylalkyl chinazolon (4) den vate, Verfahren zu deren Herstellung und sie enthaltende Arzneimittel
NL7204972A (es) 1971-04-21 1972-10-24
US3897432A (en) 1971-04-21 1975-07-29 Merck & Co Inc Substituted benzimidazole derivatives
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
DE2644265C2 (de) 1976-09-30 1983-02-10 Bayer Ag, 5090 Leverkusen Chinazoline
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4183931A (en) 1977-09-08 1980-01-15 Research Corporation 2-Ketoalkyl-4(3H)-quinazolinones
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
DE2812635A1 (de) 1978-03-22 1979-09-27 Bayer Ag Heterocyclische verbindungen
JPS55118918A (en) 1979-03-06 1980-09-12 Mitsubishi Electric Corp Production of quinazolone ring-containing epoxy resin
JPS55118917A (en) 1979-03-06 1980-09-12 Mitsubishi Electric Corp Production of quinazolone ring-containing epoxy resin
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
JPS6017375B2 (ja) 1979-06-20 1985-05-02 三菱電機株式会社 ポリアミド樹脂の製造方法
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
USRE35862E (en) 1986-08-18 1998-07-28 Emisphere Technologies, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
CH671155A5 (es) 1986-08-18 1989-08-15 Clinical Technologies Ass
US6696250B1 (en) 1986-12-03 2004-02-24 Competitive Technologies, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
EP0364598A4 (en) 1988-03-02 1992-01-15 Yoshitomi Pharmaceutical Industries, Ltd. 3,4-dihydrothieno 2,3-d¨pyrimidine compounds and pharmaceutical application thereof
US5225347A (en) 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Therapeutic ribozyme compositions and expression vectors
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
FR2675803B1 (fr) 1991-04-25 1996-09-06 Genset Sa Oligonucleotides fermes, antisens et sens et leurs applications.
EP0525960B1 (en) 1991-06-18 1996-03-20 American Home Products Corporation Use of rapamycin for the treatment of adult T-cell leukemia/lymphoma
JPH07505915A (ja) 1992-04-14 1995-06-29 コーネル　リサーチ　ファウンデーション、インコーポレーテッド 樹枝状巨大分子およびその製造法
US5658780A (en) 1992-12-07 1997-08-19 Ribozyme Pharmaceuticals, Inc. Rel a targeted ribozymes
GB9301000D0 (en) 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
US5378725A (en) 1993-07-19 1995-01-03 The Arizona Board Of Regents Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
FI951367A7 (fi) 1994-03-28 1995-09-29 Japan Energy Corp Puriinijohdannaiset ja tulehdustautien tukahduttajat (suppressantit)
US5480906A (en) 1994-07-01 1996-01-02 Eli Lilly And Company Stereochemical Wortmannin derivatives
JPH10507441A (ja) 1994-08-12 1998-07-21 プロ−ニューロン， インコーポレイテッド オキシプリンヌクレオシドを用いる敗血症または炎症性疾患の処置方法
US5561138A (en) 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
JP3233802B2 (ja) 1994-12-15 2001-12-04 関西電力株式会社 燃焼排ガス中の炭酸ガスと窒素酸化物を除去する方法
US6043062A (en) 1995-02-17 2000-03-28 The Regents Of The University Of California Constitutively active phosphatidylinositol 3-kinase and uses thereof
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5948664A (en) 1996-02-29 1999-09-07 The Regents Of The University Of California PI 3-kinase polypeptides
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
TR199802296T2 (xx) 1996-05-15 1999-02-22 Pfizer Inc. Yeni 2,3 dis�bstit�te-4 (3H)-kinazolinonlar
GB9611460D0 (en) 1996-06-01 1996-08-07 Ludwig Inst Cancer Res Novel lipid kinase
US5858753A (en) 1996-11-25 1999-01-12 Icos Corporation Lipid kinase
ATE246190T1 (de) 1996-12-31 2003-08-15 Reddys Lab Ltd Dr Heterozyklische verbindungen, verfahren zu ihrer herstellung, pharmazeutische zusammensetzungen die diese enthalten und ihre anwendung in der behandlung von diabetis und verwandten krankheiten
GB9702701D0 (en) 1997-02-01 1997-04-02 Univ Newcastle Ventures Ltd Quinazolinone compounds
HUP0000935A3 (en) 1997-02-28 2002-04-29 Pfizer Prod Inc Atropisomers of 3-heteroaryl-4(3h)-quinazolinones and their use for the treatment of neurodegenerative and cns-trauma related conditions
IL130900A0 (en) 1997-02-28 2001-01-28 Pfizer Prod Inc Atropisomers of 3-aryl-4(3H)- quinazolinones and their use as ampa-receptor antagonsts
DE69831446T2 (de) 1997-06-09 2006-06-14 Pfizer Prod Inc Chinazolin-4-on AMPA Antagonisten
WO1999001139A1 (en) 1997-07-03 1999-01-14 Thomas Jefferson University An improved method for design and selection of efficacious antisense oligonucleotides
IL125950A0 (en) 1997-09-05 1999-04-11 Pfizer Prod Inc Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
JP2002500188A (ja) 1998-01-08 2002-01-08 ザ・ユニバーシティ・オブ・バージニア・パテント・ファウンデーション Ａ２ａアデノシンレセプター作動因子
AU1120599A (en) 1998-04-23 1999-03-08 Dr. Reddy's Research Foundation New heterocyclic compounds and their use in medicine, process for their reparation and pharmaceutical compositions containing them
US6048970A (en) 1998-05-22 2000-04-11 Incyte Pharmaceuticals, Inc. Prostate growth-associated membrane proteins
US6100090A (en) 1999-06-25 2000-08-08 Isis Pharmaceuticals Inc. Antisense inhibition of PI3K p85 expression
US6046049A (en) 1999-07-19 2000-04-04 Isis Pharmaceuticals Inc. Antisense modulation of PI3 kinase p110 delta expression
EP1939203B1 (en) 2000-04-25 2014-11-19 ICOS Corporation Inhibitors of human phosphatidyl-inositol 3-kinase delta isoform
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
HRP20020838A2 (en) 2000-04-25 2004-12-31 Icos Corp Inhibitors of human phosphatidyl-inositol 3-kinase delta
CA2493843C (en) 2002-07-10 2012-04-17 Applied Research Systems Ars Holding N.V. Azolidinone-vinyl fused-benzene derivatives
US20040092561A1 (en) 2002-11-07 2004-05-13 Thomas Ruckle Azolidinone-vinyl fused -benzene derivatives
GB0217777D0 (en) 2002-07-31 2002-09-11 Novartis Ag Organic compounds
US20040023390A1 (en) 2002-08-05 2004-02-05 Davidson Beverly L. SiRNA-mediated gene silencing with viral vectors
CA2400254A1 (en) 2002-09-19 2004-03-19 University Health Network Compositions and methods for treating heart disease
HRP20050375B1 (hr) 2002-09-30 2014-03-14 Bayer Intellectual Property Gmbh Taljeni azol-pirimidin derivati
CA2508601A1 (en) 2002-12-06 2004-06-24 Warner-Lambert Company Llc Benzoxazin-3-ones and derivatives thereof as inhibitors of pi3k
MXPA05006742A (es) 2002-12-20 2005-09-08 Warner Lambert Co Benzoxazinas y derivados de las mismas como inhibidores de fosfoinositido-3-quinasas.
CA2518916A1 (en) 2003-04-03 2004-10-21 Joseph R. Garlich Pi-3 kinase inhibitor prodrugs
JP2006526610A (ja) 2003-06-05 2006-11-24 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー 療法薬としてのシクロアルキルスルファニル置換ベンゾ［ｂ］チオフェン
MXPA05012953A (es) 2003-06-05 2006-02-13 Warner Lambert Co Benzo[b]tiofenos 3-arilsulfanil y 3-heteroarilsulfanil sustituidos como agentes terapeuticos.
MXPA05012894A (es) 2003-06-05 2006-02-22 Warner Lambert Co Benzofuranos 3-sustituidos como agentes terapeuticos.
CA2527573A1 (en) 2003-06-05 2004-12-16 Warner-Lambert Company Llc Cycloalkyl and heterocycloalkyl substituted benzothiophenes as therapeutic agents
US20040259926A1 (en) 2003-06-05 2004-12-23 Bruendl Michelle M. 3-Aryloxy and 3-heteroaryloxy substituted benzo[b]thiophenes as therapeutic agents
CA2527779A1 (en) 2003-06-05 2004-12-16 Warner-Lambert Company Llc 3-substituted indoles and derivatives thereof as therapeutic agents
US20050054614A1 (en) 2003-08-14 2005-03-10 Diacovo Thomas G. Methods of inhibiting leukocyte accumulation
WO2005016348A1 (en) 2003-08-14 2005-02-24 Icos Corporation Method of inhibiting immune responses stimulated by an endogenous factor
US20050239809A1 (en) * 2004-01-08 2005-10-27 Watts Stephanie W Methods for treating and preventing hypertension and hypertension-related disorders
RS55551B1 (sr) 2004-05-13 2017-05-31 Icos Corp Hinazolinoni kao inhibitori humane fosfatidilinozitol 3-kinaze delta
WO2005112935A1 (en) 2004-05-13 2005-12-01 Vanderbilt University Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis
EP1755609A1 (en) 2004-05-25 2007-02-28 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic cells
JP2008501707A (ja) * 2004-06-04 2008-01-24 アイコス、コーポレーション マスト細胞障害を処置するための方法
CA2598409A1 (en) 2005-02-17 2006-08-24 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
WO2007076085A2 (en) 2005-12-22 2007-07-05 Prolexys Pharmaceuticals, Inc . Fused pyrimidones and thiopyrimidones, and uses thereof
WO2008064018A1 (en) 2006-11-13 2008-05-29 Eli Lilly & Co. Thienopyrimidinones for treatment of inflammatory disorders and cancers
GB2467670B (en) 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
US20090131512A1 (en) 2007-10-31 2009-05-21 Dynavax Technologies Corp. Inhibition of type I in IFN production
JP5869222B2 (ja) 2008-01-04 2016-02-24 インテリカイン， エルエルシー 特定の化学的実体、組成物および方法
KR101664511B1 (ko) 2008-11-13 2016-10-11 길리아드 칼리스토가 엘엘씨 혈액 종양에 대한 요법
WO2010065923A2 (en) 2008-12-04 2010-06-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of cns disorders
BRPI1012333A2 (pt) 2009-03-24 2016-03-29 Gilead Calistoga Llc atropisômeros de derivados de 2-purinil-3-tolil-quinazolinonas e métodos de uso
JP2012524126A (ja) 2009-04-20 2012-10-11 ギリアド カリストガ リミテッド ライアビリティ カンパニー 固形腫瘍の治療方法
CN102647987A (zh) * 2009-07-21 2012-08-22 吉里德卡利斯托加公司 使用pi3k抑制剂治疗肝脏障碍
MX387728B (es) 2010-06-03 2025-03-18 Pharmacyclics Llc El uso de inhibidores de la tirosina quinasa de bruton (btk).

Also Published As

Publication number Publication date
EA019499B1 (ru) 2014-04-30
SG174529A1 (en) 2011-10-28
IL215251A0 (en) 2011-12-29
EA201171160A1 (ru) 2012-04-30
US20100249155A1 (en) 2010-09-30
AU2010229968A1 (en) 2011-10-13
US8440677B2 (en) 2013-05-14
JP2012521994A (ja) 2012-09-20
MX2011009955A (es) 2011-11-18
EP2411391A1 (en) 2012-02-01
AP2011005943A0 (en) 2011-10-31
NZ595307A (en) 2013-11-29
BRPI1012333A2 (pt) 2016-03-29
ECSP11011412A (es) 2012-03-30
CO6450655A2 (es) 2012-05-31
CN102439012A (zh) 2012-05-02
CA2756347A1 (en) 2010-09-30
WO2010111432A1 (en) 2010-09-30
KR20120002995A (ko) 2012-01-09
CL2011002359A1 (es) 2012-04-09

Similar Documents

Publication Publication Date Title
PE20120602A1 (es) ATROPISOMEROS DE 2-[(6-AMINO-9H-PURIN-9-IL)METIL]-5-METIL-3-o-TOLILQUINAZOLIN-4(3H)-ONA
CY1123549T1 (el) Σταθερη φαρμακευτικη συνθεση και μεθοδοι χρησης αυτης
MX2020003415A (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
CL2011002115A1 (es) Compuestos derivados de 5-fenil-1h-piridin-2-ona y 5-fenil-pirazin-2-ona, inhibidores de la tirosina-quinasa de bruton (btk); proceso de preparación de los compuestos, compuesto intermediario, composición farmacéutica y uso en el tratamiento de enfermedades inflamatorias y/o autoinmunes.
CO6541569A2 (es) Inhibidores de n1-pirazoloespirocetona acetil-coa carboxilasa
CR9875A (es) Inhibidores de dipeptidilo peptidasa para tratar diabetes
CR11757A (es) Compuestos de triazina como inhibidores mtor y quinasa pi3
SV2011003855A (es) Heteroarilos sustituidos
EA201100358A1 (ru) Дабигатран для чрескожной хирургической катетеризации сердца
TN2015000084A1 (fr) Pyridinones bicycliques nouvelles
BR112015021888A8 (pt) inibidores de dna-pk, seus usos e composição farmacêutica
CU23874B1 (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y su uso
UY30500A1 (es) Compuestos de azabencimidazolilo
PE20121617A1 (es) Derivados de oxazina como inhibidores de bace
PA8840801A1 (es) Derivaos de dioxa-biciclo[3.2.1]octano-2,3,4-triol
CO6382125A2 (es) Inhibidores de proteína quinasa
UY32793A (es) Compuestos inhibidores de los virus flaviviridae, composición farmacéutica que los contiene y sus usos
CR20120289A (es) Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
MA37405A1 (fr) Composés hétérocyclyle
EA200800726A1 (ru) Введение ингибиторов дипептидилпептидазы
MX2014008773A (es) Composiciones y metodos para el uso de ésteres de forbol.
UY31676A1 (es) "derivados de 3-metil-imidiazo-[1,2-b]-piridazina"
EA201390198A1 (ru) Гетероциклическое соединение
GT201400131A (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
AR081776A1 (es) Composiciones farmaceuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, proceso para la produccion de la composicion

Legal Events

Date Code Title Description
FC Refusal